Profile: OXiGENE Inc (OXGN.OQ)

OXGN.OQ on NASDAQ Stock Exchange Capital Market

2.89USD
2 Aug 2013
Price Change (% chg)

$0.08 (+2.85%)
Prev Close
$2.81
Open
$2.85
Day's High
$2.89
Day's Low
$2.85
Volume
349
Avg. Vol
8,310
52-wk High
$9.36
52-wk Low
$2.35

Search Stocks

OXiGENE, Inc. (OXiGENE), incorporated in 1988, is a clinical-stage, biopharmaceutical company developing therapeutics primarily to treat cancer. The Company’s primary focus is the development of product candidates referred to as vascular disrupting agents (VDAs), that disable and destroy abnormal blood vessels that provide solid tumors a means of growth and survival and also are associated with visual impairment in a number of ophthalmological diseases and conditions. ZYBRESTAT is its lead candidate. It is evaluating ZYBRESTAT in a randomized, controlled Phase II clinical trial, which it refer to as the FALCON trial, as a first-line treatment for stage IIIB/IV non-small cell lung cancer (NSCLC). In the FALCON trial, patients are randomized either to the treatment arm of study, in which they receive YBRESTAT in combination with the chemotherapeutic agents, carboplatin and paclitaxel, and bevacizumab, a drug that interferes with blood vessel growth, or angiogenesis, or to the control arm of the study, in which they received a standard combination regimen of carboplatin, paclitaxel and bevacizumab.

The Company is pursuing development of OXi4503, a second-generation, dual-mechanism VDA, as a treatment for certain solid tumor types and for the treatment of myeloid leukemias. Xi4503 has shown potent anti-tumor activity against solid tumors and acute myeloid leukemia models, both as a single agent and in combination with other cancer treatment modalities. It has completed a Phase 1 clinical trial of OXi4503 in patients with advanced solid tumors sponsored by Cancer Research United Kingdom. In addition to developing ZYBRESTAT as an intravenously administered therapy for oncology indications, OXiGENE is undertaking an ophthalmology research and development program with ZYBRESTAT, the objective of which is to develop a topical formulation of ZYBRESTAT for ophthalmological diseases and conditions that are characterized by abnormal blood vessel growth within the eye that results in loss of vision.

Company Address

OXiGENE Inc

Suite 210, 701 Gateway Blvd
SOUTH SAN FRANCISCO   CA   94080
P: +1650.6357000
F: +1650.6357001

Search Stocks